William D Stern

US Patent:

6440392, Aug 27, 2002

Filed:

Feb 2, 2001

Appl. No.:

09/776537

Inventors:

William Stern - Tenafly NJ

Assignee:

Unigene Laboratories, Inc. - Fairfield NJ

International Classification:

A61K 912

US Classification:

424 43, 424 45, 424455, 514 2, 514 3, 514 12

Abstract:

A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.

US Patent:

6473915, Nov 5, 2002

Filed:

Jun 11, 2001

Appl. No.:

09/878678

Inventors:

Barry Davis - Farmingdale NY
William A. Stern - Scarsdale NY

Assignee:

Aqua-Eez, Inc. - Yonkers NY

International Classification:

A47K 302

US Classification:

4555, 4584, 4556, 4593

Abstract:

A hydrotherapy pool comprising an enclosure for receiving a patient and for holding a quantity of liquid sufficient for immersing the patient so that the patient receives hydrotherapy, the enclosure having a plurality of openings for facilitating entry and exit from the enclosure; a removable door for each opening; a water tight seal for each door for sealing the door to the enclosure so that water does not leak from the enclosure; and a filling and draining system for filling and draining the enclosure of water. A seating area at a first end of the pool. The pool may have three doors, the doors being disposed with respect to the patient when seated in the seating area facing the patient, to the right of the patient, and to the left of the patient. Each door may comprise a panel having a shape corresponding to the openings; a seal disposed about the periphery of the panel; at least one locking mechanism for urging the seal into contact with a portion of the enclosure associated with the opening so that the seal is trapped between the door and that portion.

US Patent:

6673574, Jan 6, 2004

Filed:

Nov 29, 2001

Appl. No.:

09/997465

Inventors:

William Stern - Tenafly NJ
Nozer M. Mehta - Randolph NJ
Martha V. L. Ray - Nutley NJ

Assignee:

Unigene Laboratories Inc. - Fairfield NJ

International Classification:

C12P 2104

US Classification:

435 697, 435183, 5303873, 4241841, 4241921, 4241931

Abstract:

Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine in addition to having the active peptide linked to a membrane translocator which is capable of being at least partially cleaved in vivo by an enzyme. The composition includes an acid-resistant protective vehicle which transports components of the invention through the stomach and a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

US Patent:

RE40812, Jun 30, 2009

Filed:

Feb 5, 2004

Appl. No.:

10/774358

Inventors:

William Stern - Tenafly NJ, US

Assignee:

Unigene Laboratories Inc. - Boonton NJ

International Classification:

A61K 9/12
A61K 9/00
A61K 38/23

US Classification:

424434, 424 45, 424455, 514 2, 514 3, 514 12

Abstract:

p-00010000.

US Patent:

8093207, Jan 10, 2012

Filed:

Dec 6, 2006

Appl. No.:

11/567454

Inventors:

William Stern - Tenafly NJ, US

Assignee:

Unigene Laboratories, Inc. - Boonton NJ

International Classification:

A61K 38/00
A61K 47/12

US Classification:

514 11, 424465, 562584

Abstract:

A finished pharmaceutical product adapted for oral delivery of a physiologically active peptide agent, wherein the product comprises a therapeutically effective amount of the active peptide agent; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent, wherein the pH-lowering agent is present in the finished pharmaceutical product in a quantity which, if the product were added to 10 milliliters of 0. 1M aqueous sodium bicarbonate solution, would be sufficient to lower the pH of the solution to no higher than 5. 5, and wherein an outer surface of the product is substantially free of an acid-resistant protective vehicle. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic peptide active agent delivered orally.

US Patent:

RE43580, Aug 14, 2012

Filed:

Jun 29, 2009

Appl. No.:

12/459385

Inventors:

William Stern - Tenafly NJ, US

Assignee:

Unigene Laboratories, Inc. - Boonton NJ

International Classification:

A61K 9/12
A61K 9/00
A61K 38/23

US Classification:

424 43, 424 45, 424455, 514 2, 514 3, 514 12

Abstract:

p-00010000.

US Patent:

8377863, Feb 19, 2013

Filed:

May 28, 2008

Appl. No.:

12/128210

Inventors:

William Stern - Tenafly NJ, US
Angelo P. Consalvo - Monroe NY, US

Assignee:

Unigene Laboratories Inc. - Boonton NJ

International Classification:

A61K 38/00
A61K 47/12

US Classification:

514 11, 424465, 562400

Abstract:

Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i. e. , those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.

US Patent:

8513183, Aug 20, 2013

Filed:

Oct 27, 2011

Appl. No.:

13/283055

Inventors:

William Stern - Tenafly NJ, US
Angelo P. Consalvo - Monroe NY, US

Assignee:

Enteris Biopharma, Inc. - Boonton NJ

International Classification:

A61K 38/00
A61K 47/12

US Classification:

514 11, 562400, 562584, 424465

Abstract:

Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i. e. , those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.

Address:

17 Florence Ave, Freeport, NY 11520

VIN:

JHLRE48777C120178

Make:

HONDA

Model:

CR-V

Year:

2007